REFERENCES
- Bertani T, Rocchi G, Sacchi G, Mecca G, Remuzzi G. Adriamycin-induced glomerulosclerosis in the rat. Am J Kidney Dis 1986; 7: 12–19
- Mampaso F M, Egido J, Martinez-Montero J C, Bricio T, Gonzalez E, Cobo M E, Pirotzky E, Braquet P, Hernando L. Interstitial mononuclear cell infiltrates in experimental nephrosis: effect of PAF antagonist. Nephrol Dial Transplant 1989; 4: 1037–1044
- Rossmann P, Matousovic K, Bohdanecka M. Experimental adriamycin nephropathy. Fine structure, morphometry, glomerular polyanion, and cell membrane antigens. J Pathol 1993; 169: 99–108
- Ginevri F, Trivelli A, Mutti A, Bergamaschi E, Fabbretti G, Callea F, Salvidio G, Altieri P, Perfumo F, Ghiggeri G M. Progression of chronic adriamycin nephropathy in leukopenic rats. Nephron 1993; 63: 79–88
- Soares V A. Effects of cyclosporin on adriamycin nephropathy. Nephrology 1996; 4: 576–584
- Amore A, Mazzucco G, Cavallo F, Forni G, Gianoglio B, Motta M, Peruzzi L, Novelli F, Porcellini M G, Cesano G, Coppo R. Adriamycin-induced proteinuria in nude mice: an immune-system-mediated toxic effect. Nephrol Dial Transplant 1996; 11: 1012–1018
- Allison A C, Eugui E M. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996; 10: 77–84
- Allison A C, Eugui E M. Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc 1994; 26: 3205–3210
- Sollinger H W. Mycophenolate mofetil. Kidney Int Suppl 1995; 52: S14–S17
- Eugui E M, Allison A C. Immunosuppressive activity of mycophenolate mofetil. Ann N Y Acad Sci 1993; 685: 309–329
- Hughes S E, Gruber S A. New immunosuppressive drugs in organ transplantation. J Clin Pharmacol 1996; 36: 1081–1092
- Switzer B R. Determination of hidroxyproline in tissue. J Nutr Biochem 1991; 2: 229–231
- Corna D, Morigi M, Facchinetti D, Bertani T, Zoja C, Remuzzi G. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 1997; 51: 1583–1589
- Jonsson C A, Svensson L, Carlsten H. Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice. Clin Exp Immunol 1999; 116: 534–541
- Van Bruggen M C, Walgreen B, Rijke T P, Berden J H. Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 1998; 9: 1407–1415
- Penny M J, Boyd R A, Hall B M. Mycophenolate mofetil prevents the induction of active Heymann nephritis: association with Th2 cytokine inhibition. J Am Soc Nephrol 1998; 9: 2272–2282
- Fujihara C K, Malheiros D M, Zatz R, Noronha I D. Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 1998; 54: 1510–1519
- Romero F, Rodriguez-Iturbe B, Parra G, Gonzalez L, Herrera-Acosta J, Tapia E. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999; 55: 945–955
- Fujihara C K, De L N, Malheiros I, Antunes G R, de Oliveira I B, Zatz R. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 2000; 11: 283–290
- Carvalho M F, Viero R M, Soares V A. Effect of allopurinol in the course of adriamycin induced nephropathy. Ren Fail 1999; 21: 147–154
- Riyuzo M C, Soares V A. Role of ticlopidine on adriamycin-induced nephropathy. Ren Fail 1999; 21: 469–475